Zachary Beau Reneer

Dr. Zachary Beau Reneer

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2020 in Science
Verified
Journal Article
Open access
PDF file
TLThomas W. Linsky
Thomas W. Linsky
RVRenan Vergara
Renan Vergara
NCNuria Codina
Nuria Codina
JNJorgen W. Nelson
Jorgen W. Nelson
MWMatthew J. Walker
Matthew J. Walker
DSDaniel-Adriano Silva
Daniel-Adriano Silva
A decoy to neutralize SARS-CoV-2: Many efforts to develop therapies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are focused on the interaction between the spike protein, which decorates the surface of the virus, and its host receptor, human angiotensin-converting enzyme 2 (hACE2). Linsky et al. describe a de novo design strategy that allowed them to engineer decoy proteins that bind to the spike protein by replicating the hACE2 interface. The best decoy, CTC-445, bound with low nanomolar affinity, and selection of viral mutants that decrease binding is unlikely because this would also affect binding to hACE2. A bivalent version of CTC-445 bound even more tightly, neutralized SARS-CoV-2 infection of cells, and protected hamsters from a SARS-CoV-2 challenge. The stable decoy has the potential for respiratory therapeutic delivery. Science , this issue p. 1208

22 December 2020 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
ZRZachary Beau Reneer
Zachary Beau Reneer
PJParker J. Jamieson
Parker J. Jamieson
ASAmanda L. Skarlupka
Amanda L. Skarlupka
YHYing Huang
Ying Huang
TRTed Ross
Ted Ross
H2N2 influenza has caused at least one pandemic in the past. Given that individuals born after 1968 have not been exposed to H2N2 influenza viruses, a future pandemic caused by H2 influenza is likely. An effective H2 influenza vaccine would need to elicit broadly cross-reactive antibodies to multiple H2 influenza viruses. Choosing a wild-type virus to create a vaccine may elicit a narrow immune response and not protect against multiple H2 influenza viruses. COBRA H2 HA vaccines were developed and evaluated in mice along with wild-type H2 HA vaccines. Multiple COBRA H2 HA vaccines protected mice from all three viral challenges and produced broadly cross-reactive neutralizing antibodies to H2 influenza viruses.

28 April 2021 in mSphere
Verified
Journal Article
Open access
PDF file
ZRZachary Beau Reneer
Zachary Beau Reneer
ASAmanda L. Skarlupka
Amanda L. Skarlupka
PJParker J. Jamieson
Parker J. Jamieson
TRTed Ross
Ted Ross
H1N1 and H3N2 influenza viruses have cocirculated in the human population since 1977. Nearly every human alive today has antibodies and memory B and T cells against these two subtypes of influenza viruses.


18 April 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ZRZachary Beau Reneer
Zachary Beau Reneer
HBHarrison Bergeron
Harrison Bergeron
SRStephen Reynolds
Stephen Reynolds
ETElena Thornhill-Wadolowski
Elena Thornhill-Wadolowski
LFLan Feng
Lan Feng
Ralph TrippRalph Tripp
Ralph Tripp
Influenza viruses cause epidemics and can cause pandemics with substantial morbidity with some mortality every year. Seasonal influenza vaccines have incomplete effectiveness and elicit a narrow antibody response that often does not protect against mutations occurring in influenza viruses. Thus, various vaccine approaches have been investigated to improve safety and efficacy. Here, we evaluate an mRNA influenza vaccine encoding hemagglutinin (HA) proteins in a BALB/c mouse model. The results show that mRNA vaccination elicits neutralizing and serum antibodies to each influenza virus strain contained in the current quadrivalent vaccine that is designed to protect against four different influenza viruses including two influenza A viruses (IAV) and two influenza B (IBV), as well as several antigenically distinct influenza virus strains in both hemagglutination inhibition assay (HAI) and virus neutralization assays. The quadrivalent mRNA vaccines had antibody titers comparable to the antibodies elicited by the monovalent vaccines to each tested virus regardless of dosage following an mRNA booster vaccine. Mice vaccinated with mRNA encoding an H1 HA had decreased weight loss and decreased lung viral titers compared to mice not vaccinated with an mRNA encoding an H1 HA. Overall, this study demonstrates the efficacy of mRNA-based seasonal influenza vaccines are their potential to replace both the currently available split-inactivated, and live-attenuated seasonal influenza vaccines.

12 July 2021 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
Abhijeet BakreAbhijeet Bakre
Abhijeet Bakre
LJLes P. Jones
Les P. Jones
JMJackelyn Murray
Jackelyn Murray
ZRZachary Beau Reneer
Zachary Beau Reneer
VMVictoria A. Meliopoulos
Victoria A. Meliopoulos
Ralph TrippRalph Tripp
Ralph Tripp
Swine are considered intermediate hosts that have facilitated influenza virus reassortment events that have given rise pandemics or genetically related viruses have become established in swine. In this study, we examine the innate antiviral response to swine influenza virus in primary and immortalized swine nasal and tracheal epithelial cells, and show virus strain- and host cell type-dependent differential expression of key interferons and interferon-stimulated genes.